Background and objectives: Thoracoscopic sympathectomy, for years an effect
ive way to treat mainly palmar and axillar hyperhidrosis, experienced a rev
ival since the application of the principles of minimally invasive surgery.
We report the personal experiences of three surgeons with this technique,
as well as patients' view of the outcome.
Patients and methods: Between January 1990 and November 1997, 73 procedures
were performed in 43 patients (23 males, 20 females, mean age 38.1 years,
range 15-82 years), and the outcome was prospectively studied. Palmar hyper
hidrosis without axillar symptoms was the indication for the operation in 2
7 patients (54 sympathectomies), Raynaud's syndrome in 15 (18 sympathectomi
es), and causalgia in one. Thoracic ganglia 2-4 were always completely rese
cted. Perioperative morbidity as well as patient satisfaction in the long-t
erm course (standardized interview) 25.8 (1-77) months postoperatively were
assessed.
Results: The complication rate in all 73 sympathectomies was 8.2%. Only two
severe incidents were observed: in one patient intermittent Horner's syndr
ome (1.4%) occurred, and in another severe bleeding required conversion to
open surgery (1.4%). Both complications occurred in the early study phase.
The initial success rate in all 27 patients with hyperhidrosis was 100%. In
30% of these cases a mild partial relapse was observed, which did not inte
rfere with their daily activities. 53% of the patients reported compensator
y and 23% gustatory sweating. 9% would have refused the operation, had they
known these side effects. In all patients with Raynaud's disease the ulcer
ations healed completely. At the time of the interview, two patients (13%)
complained of painless relapses. They too stated that they had refused the
operation, if they had known about the relapses.
Conclusions: Even in the longer-term course, thoracoscopic sympathectomy is
rated subjectively successful by 93% of patients after treatment of hyperh
idrosis of the upper extremities, and by 87% of patients after treatment of
Raynaud's disease, despite some untoward effects and partial relapses.